G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET
Company Participants
Will Roberts - VP, Communications
Jack Bailey - CEO
Raj Malik - CMO
Andrew Perry - CCO
Jen Moses - CFO
Conference Call Participants
Gil Blum - Needham & Company
Dane Leone - RJF
Ed White - H.C. Wainwright
Malcolm Kuno - JPM
David Nierengarten - Wedbush PacGrow
Troy Langford - Cowen and Company
Tony Butler - ROTH Capital Partners
Operator
Hello and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions].
I would now like to hand the conference over to your opening speaker, Vice President of Communications, Will Roberts. Will, please proceed.
Will Roberts
Thank you, Sheena. Good morning, everyone, and welcome to the G1 conference call to discuss our third quarter 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our corporate website g1therapeutics.com.
On this morning's call, the team will provide a business overview of the third quarter of 2022, including an update on our clinical programs and our commercial progress in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide continue regimen or a topotecan containing regimen for extensive stage small cell lung cancer or ES-SCL. A Q&A session as Sheena said will follow the prepared remarks.
Before I begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve certain risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements.
For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, November 2, 2022.
Joining me on the call today are Jack Bailey, our Chief Executive Officer; Raj Malik, our Chief Medical Officer; Andrew Perry, our Chief Commercial Officer; and Jen Moses, our Chief Financial Officer.